within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01X_OtherAntibacterials.J01XA05_Oritavancin;
model Oritavancin 
   extends Pharmacolibrary.Drugs.ATC.J.J01XA05;

  annotation(Documentation(
    info ="<html><body><p>Oritavancin is a semisynthetic lipoglycopeptide antibiotic used for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is approved for use in adults and is administered as a single intravenous dose.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in healthy adult subjects receiving a single intravenous dose.</p><h4>References</h4><ol><li><p>Lehoux, D, et al., &amp; Parr, TR (2015). Oritavancin Pharmacokinetics and Bone Penetration in Rabbits. <i>Antimicrobial agents and chemotherapy</i> 59(10) 6501–6505. DOI:<a href=&quot;https://doi.org/10.1128/AAC.00981-15&quot;>10.1128/AAC.00981-15</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26239977/&quot;>https://pubmed.ncbi.nlm.nih.gov/26239977</a></p></li><li><p>Nau, R, et al., &amp; Eiffert, H (2024). New Antibiotics for the Treatment of Nosocomial Central Nervous System Infections. <i>Antibiotics (Basel, Switzerland)</i> 13(1) –. DOI:<a href=&quot;https://doi.org/10.3390/antibiotics13010058&quot;>10.3390/antibiotics13010058</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38247617/&quot;>https://pubmed.ncbi.nlm.nih.gov/38247617</a></p></li><li><p>Bhavnani, SM, et al., &amp; Ambrose, PG (2004). Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. <i>Diagnostic microbiology and infectious disease</i> 50(2) 95–102. DOI:<a href=&quot;https://doi.org/10.1016/j.diagmicrobio.2004.06.007&quot;>10.1016/j.diagmicrobio.2004.06.007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15474317/&quot;>https://pubmed.ncbi.nlm.nih.gov/15474317</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Oritavancin;
